4Filed Sep 8, 8:00 PM ET

Vaxcyte (PCVX) EVP Jim Wassil Sells Shares

$PCVX · Vaxcyte, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

Vaxcyte (PCVX) EVP Jim Wassil Sells Shares

What Happened

  • Jim Wassil, EVP, Chief Scientific Officer and COO of Vaxcyte (PCVX), recorded three dispositions in early September 2026 totaling 8,174 shares for about $493,368.
    • 2026-09-04: Sold 1,381 shares at a weighted-average price of $61.16 for $84,462.
    • 2026-09-08: Surrendered 5,459 shares at $60.36 (to cover tax withholding on RSU vesting) for $329,505.
    • 2026-09-09: Sold 1,334 shares at a weighted-average price of $59.52 for $79,401.
  • These were sales/surrenders (not purchases); sales are commonly routine or for tax/financial reasons rather than a direct bullish signal.

Key Details

  • Transaction dates/prices:
    • 9/4/2026 — 1,381 shares sold @ weighted-average $61.16 (range $60.95–$61.57 per footnote).
    • 9/8/2026 — 5,459 shares surrendered @ $60.36 to cover tax withholding on RSUs.
    • 9/9/2026 — 1,334 shares sold @ weighted-average $59.52 (range $59.155–$60.12 per footnote).
  • Total proceeds reported: about $493,368.
  • Shares owned after the transactions: Not specified in this Form 4 filing.
  • Notable footnotes:
    • Sales were effected pursuant to a Rule 10b5‑1 trading plan adopted 12/09/2025 (pre-arranged plan).
    • Weighted-average prices reported; per-footnotes the exact per-share prices vary within stated ranges.
    • The 5,459-share disposition represents shares surrendered to cover RSU tax withholding (cashless withholding).
  • Filing timing: Form filed 2026-09-09; the earliest reported sale occurred 2026-09-04, which appears to be outside the typical two-business-day Form 4 reporting window and thus may be a late report for that trade.

Context

  • The 9/8 transaction (code F) was a tax withholding event tied to RSU vesting — a common administrative action where shares are surrendered rather than sold on the open market by the insider.
  • Sales under a Rule 10b5‑1 plan are pre-planned trades and are generally treated as routine; they do not necessarily indicate the insider’s current view of the company.
  • For retail investors, purchases are often more informative about insider sentiment than routine sales or tax-related surrenders.